title: Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
abstract: A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMkappa-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20(+) cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of amyloidogenic immunoglobulin light chains.
authors: Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
authors: Ko-Ichi
authors: K
authors: Tazawa
authors: Nagaaki
authors: N
authors: Katoh
authors: Yasuhiro
authors: Y
authors: Shimojima
authors: Masayuki
authors: M
authors: Matsuda
authors: Shu-Ichi
authors: S
authors: Ikeda
mesh_terms: D000686:Amyloidosis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D008206:Lymphatic Diseases / Q000097:blood / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D011859:Radiography
chemical_list: D018906:Antineoplastic Agents, Alkylating; D007075:Immunoglobulin M; D008558:Melphalan